Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | IAPP | P10997 | 1/20 | 0.34 |
| ▸ | TFEB | P19484 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661727 | 0.85 | MAPT (0.47) | MAPTLMNAKDM4ECYP3A4ALOX15 | |
| SCHEMBL24425997 | 0.83 | CYP3A4 (0.45) | MAPTLMNAKDM4ECYP3A4IAPP | |
| SCHEMBL31310317 | 0.80 | MAPT (0.63) | MAPTLMNAKDM4ESMN1; SMN2NFE2L2 | |
| SCHEMBL12569874 | 0.80 | MAPT (0.63) | MAPTLMNAKDM4ESMN1; SMN2NFE2L2 | |
| SCHEMBL14257702 | 0.79 | NFE2L2 (0.40) | MAPTLMNAKDM4ECYP3A4NFE2L2 | |
| SCHEMBL8349013 | 0.78 | TSHR (0.45) | MAPTLMNAKDM4ESMN1; SMN2NFE2L2 | |
| SCHEMBL2961735 | 0.78 | TSHR (0.45) | MAPTLMNAKDM4ESMN1; SMN2NFE2L2 | |
| SCHEMBL10962113 | 0.78 | MAPT (0.66) | MAPTLMNAKDM4ENFE2L2NFKB1 | |
| SCHEMBL13680308 | 0.76 | LMNA (0.52) | MAPTLMNAKDM4ESMN1; SMN2NFE2L2 | |
| SCHEMBL16507826 | 0.76 | CD44 (0.41) | MAPTLMNAKDM4EIAPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-01-12 | — | — | US | disclosed |
| EP-1869025-B3 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100178654-A1 | REAGENT AND REAGENT KIT FOR ANALYSIS OF IMMATURE LEUKOCYTE | SYSMEX CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2067767-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2005013947-A2 | MEANS AND METHODS FOR TREATING A DISEASE WHICH IS ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN ACROSS A LIPID BILAYER | Universitätsklinikum Münster (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | MAPT 1431/4885LMNA 3998/4885KDM4E 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.